Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
<h4>Background</h4>Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu). Up to 70% of Her2-positive breast cancers demonstrate a response to Herceptin-based therapies,...
Guardado en:
Autores principales: | Long Gu, Sarah Waliany, Susan E Kane |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/44da831265354ae09157b44d2cf221c9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Spatial distribution of DARPP-32 in dendritic spines.
por: Hans Blom, et al.
Publicado: (2013) -
DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration
por: Sk. Kayum Alam, et al.
Publicado: (2018) -
Ultrasound-triggered herceptin liposomes for breast cancer therapy
por: Amal Elamir, et al.
Publicado: (2021) -
Internalization: acute apoptosis of breast cancer cells using herceptin-immobilized gold nanoparticles
por: Rathinaraj P, et al.
Publicado: (2015) -
Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)